US2021338593A1PendingUtilityA1

Multistage delivery of active agents

Assignee: UNIV TEXASPriority: Aug 8, 2006Filed: Jul 6, 2021Published: Nov 4, 2021
Est. expiryAug 8, 2026(~0 yrs left)· nominal 20-yr term from priority
A61K 9/51A61K 9/1271A61K 31/165A61K 31/7088A61K 9/127A61K 31/704A61K 9/50
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A multistage delivery composition comprising:
 a first stage particle containing a second stage particle,   
       wherein the first stage particle comprises:
 (i) a body; 
 (ii) at least one surface with a surface charge; and 
 (iii) a plurality of nanoscale reservoirs in the body of the first stage particle, each reservoir connected to at least one surface of the body, such that at least one of the plurality of the nanoscale reservoirs contains the second stage particle, and 
 wherein the first stage particle is biodegradable and has a selected non-spherical shape; 
 the first stage particle is a porous micro or nanoparticle with a size from about 100 nm to about 5 microns; 
 the second stage particle comprises an active agent; 
 the first stage particle is configured to overcome a first biological barrier; and 
 the second stage particle is configured to overcome a second biological barrier, wherein the first stage particle and the second stage particle are configured to sequentially overcome the first biological barrier and second barrier respectively. 
 
     
     
         2 . The multistage delivery composition of  claim 1  wherein the first stage particle is configured to release the second stage particle for delivery of the active agent. 
     
     
         3 . The multistage delivery composition of  claim 1  wherein the first stage particle is configured to release the second stage particle for delivery of the active agent via diffusion of the second stage particle through the channels in the first stage particle. 
     
     
         4 . The multistage delivery composition of  claim 1  wherein the first stage particle is configured to release the second stage particle for delivery of the active agent via degradation or erosion of the body the first stage particle. 
     
     
         5 . The multistage delivery composition of  claim 1  wherein the first biological barrier and the second biological barrier are each independently selected from the group of biological barriers consisting of a hemo-rheology barrier, a reticuloendothelial system barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier, and any combination of thereof. 
     
     
         6 . The multistage delivery composition of  claim 1  wherein the first stage particle comprises a chemical targeting moiety disposed on the surface of the first stage particle, wherein said chemical targeting moiety comprises at least one moiety selected from the group consisting of dendrimer, an aptamer, an antibody, a biomolecule and any combination thereof. 
     
     
         7 . The multistage delivery composition of  claim 1  wherein at least one of the plurality of nanoscale reservoirs contains at least one additional agent. 
     
     
         8 . The composition of  claim 7 , wherein the at least one additional agent comprises at least one penetration enhancer, at least one additional active agent, or at least one targeting moiety. 
     
     
         9 . The composition of  claim 8 , wherein the at least one penetration enhancer is selected from the group consisting of a basement membrane permeation enhancer, a tight junction protein (tjp) permeation enhancer and any combination thereof. 
     
     
         10 . The composition of  claim 1 , wherein the first stage particle is configured to release the second stage particle in response to an external stimulus. 
     
     
         11 . The composition of  claim 1 , wherein the second stage particle comprises at least one constituent selected from the group consisting of a liposome, a micelle, an ethosome, a carbon nanotube, a fullerene nanoparticle, a metal nanoparticle, a semiconductor nanoparticle, a polymer nanoparticle, an oxide nanoparticle, a viral particle, a polyionic particle and a ceramic particle. 
     
     
         12 . A method comprising administering to a subject a composition comprising:
 a first stage particle containing a second stage particle, wherein the first stage particle comprises:   (i) a body;   (ii) at least one surface with a surface charge; and   (iii) a plurality of nanoscale reservoirs in the body of the first stage particle, each reservoir connected to at least one surface of the body, such that at least one of the plurality of the nanoscale reservoirs contains the second stage particle, and wherein:   the first stage particle is biodegradable and has a selected non-spherical shape;   the first stage particle is a porous micro or nanoparticle with a size from about 100 nm to about 5 microns;   the second stage particle comprises an active agent;   the first stage particle is configured to overcome a first biological barrier; and   the second stage particle is configured to overcome a second biological barrier, wherein   the first stage particle and the second stage particle are configured to sequentially overcome the first biological barrier and second barrier respectively.   
     
     
         13 . The method of  claim 12  wherein the first stage particle is configured to release the second stage particle for delivery of the active agent. 
     
     
         14 . The method of  claim 12  wherein the first biological barrier and the second biological barrier are each independently selected from the group of biological barriers consisting of a hemo-rheology barrier, a reticulo-endothelial system barrier, an endothelial barrier, a blood brain barrier, a tumorassociated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier, and any combination of thereof. 
     
     
         15 . The method of  claim 12  wherein the first stage particle comprises a chemical targeting moiety disposed on the surface of the first stage particle, wherein said chemical targeting moiety comprises at least one moiety selected from the group consisting of dendrimer, an aptamer, an antibody, a biomolecule and any combination thereof. 
     
     
         16 . The method of  claim 12  wherein the at least one of the plurality of nanoscale reservoirs contains at least one additional agent. 
     
     
         17 . The method of  claim 12  wherein the at least one additional agent comprises at least one penetration enhancer, at least one additional active agent, or at least one targeting moiety. 
     
     
         18 . The method of  claim 12  wherein the composition is administered intravascularly. 
     
     
         19 . A method of fabricating a multistage delivery composition, comprising:
 (a) providing a first stage particle, wherein the first stage particle comprises:   (i) a body;   (ii) at least one surface with a surface charge; and   (iii) a plurality of nanoscale reservoirs in the body of the first stage particle, each reservoir connected to at least one surface of the body, and wherein:   the first stage particle is biodegradable and has a selected non-spherical shape;   the first stage particle is a porous micro or nanoparticle with a size from about 100 nm to about 5 microns;   (b) providing a second stage particle, wherein the second stage particle comprises:   a body;   at least one active agent contained in the second stage particle; and a surface; and   (c) loading the second stage particle inside one of the plurality of nanoscale reservoirs of the first stage particle, such that the first stage particle is configured to overcome a first biological barrier and the second stage particle is configured to overcome a second biological barrier, wherein the first stage particle and the second stage particle are configured to sequentially overcome the first biological barrier and second barrier respectively.   
     
     
         20 . The method of  claim 19 , wherein loading the second stage particle inside one of the plurality of nanoscale reservoirs of the first stage particle comprises placing the first stage particle and the second stage particle in a sealed chamber having a pressure above atmospheric pressure.

Join the waitlist — get patent alerts

Track US2021338593A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.